Compare · BMRA vs TRIB
BMRA vs TRIB
Side-by-side comparison of Biomerica Inc. (BMRA) and Trinity Biotech plc (TRIB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BMRA and TRIB operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- BMRA is the larger of the two at $6.3M, about 1.3x TRIB ($5.0M).
- TRIB has hit the wire 2 times in the past 4 weeks while BMRA has been quiet.
- BMRA has more recent analyst coverage (1 ratings vs 0 for TRIB).
- Company
- Biomerica Inc.
- Trinity Biotech plc
- Price
- -
- -
- Market cap
- $6.3M
- $5.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- News (4w)
- 0
- 2
- Recent ratings
- 1
- 0
Biomerica Inc.
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Trinity Biotech plc
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. The company sells its products through its direct sales force; and a network of independent distributors and strategic partners. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Latest BMRA
- SEC Form DEF 14A filed by Biomerica Inc.
- Biomerica Reports First Quarter Fiscal 2027 Financial Results
- SEC Form 10-Q filed by Biomerica Inc.
- SEC Form 8-K filed by Biomerica Inc.
- SEC Form EFFECT filed by Biomerica Inc.
- SEC Form EFFECT filed by Biomerica Inc.
- Amendment: SEC Form 10-K/A filed by Biomerica Inc.
- SEC Form S-3 filed by Biomerica Inc.
- SEC Form S-3 filed by Biomerica Inc.
- SEC Form 3 filed by new insider Qu Xiaoxuan
Latest TRIB
- SEC Form 6-K filed by Trinity Biotech plc
- Amendment: SEC Form SCHEDULE 13D/A filed by Trinity Biotech plc
- SEC Form 6-K filed by Trinity Biotech plc
- SEC Form 6-K filed by Trinity Biotech plc
- SEC Form 6-K filed by Trinity Biotech plc
- SEC Form EFFECT filed by Trinity Biotech plc
- SEC Form 6-K filed by Trinity Biotech plc
- Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update
- SEC Form POS AM filed by Trinity Biotech plc
- SEC Form AW filed by Trinity Biotech plc